News Formal

Why Amylyx is pulling ALS drug Relyvrio from US market after study

  • 📰 AP
  • ⏱ Reading Time:
  • 41 sec. here
  • 17 min. at publisher
  • 📊 Quality Score:
  • News: 72%
  • Publisher: 51%

Medication Notícia

Lou Gehrigs Disease,General News,MA State Wire

The maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.

FILE - This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday, April 4, 2024 it will pull the medicine from the U.S. market, acknowledging it didn’t help patients with the deadly neurological condition. said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.

“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.West Virginia Gov.

The company’s voluntary action resolves what could have been a major dilemma for the FDA. The agency’s regulators would not have had a clear path to quickly force the drug from the market if the company had refused to remove it. That’s because the FDA granted the drug full approval, despite the preliminary nature of the company’s data on effectiveness.by some of the agency’s own internal scientists.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 728. in BR

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Here’s Why ALS Drug Relyvrio Is Being Removed From Market—And What That Means For PatientsI'm a Texas native covering the latest trends in tech, science and healthcare through explainer pieces on the breaking news team. Previously, I was a Forbes HBCU Scholar writing under the innovation and health and science teams.
Fonte: ForbesTech - 🏆 318. / 59 Consulte Mais informação »

Controversial ALS Drug May Be Pulled from Market After Disappointing Trial ResultsFollowing disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.
Fonte: MedicineNet - 🏆 575. / 51 Consulte Mais informação »